Prosecution Insights
Last updated: October 02, 2026

Examiner: MCKILLOP, JOHN CHARLES

Tech Center 1600 • Art Units: 1636 1637 1699

This examiner grants 62% of resolved cases

Analysis

John Charles McKillop works in Art Unit 1636 and Tech Center 1600. He has 54 resolved cases with an allowance rate of 61.1 percent. The median days to allowance is 1421. These statistics describe the prosecution history for this examiner and provide a basis for understanding the application lifecycle.

The interview lift is 41.5 percent. This figure indicates that an interview is associated with an increase in the likelihood of allowance. Practitioners can use this lift to supplement the 61.1 percent rate. The 1421 days median pendency provides a timeline for applications that reach a grant. With 54 resolved cases, the data shows a specific pattern of outcomes. The 41.5 percent lift and the Art Unit 1636 designation are data points for strategy. This profile informs the approach for applications in Tech Center 1600.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Performance Statistics

61.8%
Allow Rate
+1.8% vs TC avg
83
Total Applications
+40.3%
Interview Lift
1431
Avg Prosecution Days
Based on 55 resolved cases, 2023–2026

Rejection Statute Breakdown

4.8%
§101 Eligibility
16.8%
§102 Novelty
39.0%
§103 Obviousness
26.2%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
17602076 Enhancement of Melanocyte Migration Using ROCK Inhibitors Final Rejection The General Hospital Corporation
18273643 MATERIALS AND METHODS FOR THE TREATMENT OF LYSOSOMAL ACID LIPASE DEFICIENCY (LAL-D) Non-Final OA RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL
18146818 COMPOSITION FOR PREVENTING OR TREATING ALZHEIMER'S DISEASE COMPRISING INHIBITOR OF ATLASTIN 2, AND METHOD FOR DIAGNOSING ALZHEIMER'S DISEASE BY DETERMINING ATLASTIN 2 Non-Final OA Research & Business Foundation Sungkyunkwan University
17619633 DELIVERY OF OLIGONUCLEOTIDES TO THE STRIATUM Final Rejection ALNYLAM PHARMACEUTICALS, INC.

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month